Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(67%)

Phase Distribution

Ph phase_2
2
67%
Ph not_applicable
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(2)
Other(1)

Detailed Status

Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 22 (66.7%)
N/A1 (33.3%)

Trials by Status

terminated267%
unknown133%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_2

PET Study to Study Tumour Apoptosis

NCT01428440
unknownnot_applicable

Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer

NCT01254591
terminatedphase_2

18F ML-10 for Early Detection of Response of Brain Metastases to SRS

NCT00696943

Clinical Trials (3)

Showing 3 of 3 trials
NCT01428440Phase 2

PET Study to Study Tumour Apoptosis

Terminated
NCT01254591Not Applicable

Positron Emission Tomography/Computed Tomography Scanning Before Surgery in Patients With Non-Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Esophageal Cancer, or Head and Neck Cancer

Unknown
NCT00696943Phase 2

18F ML-10 for Early Detection of Response of Brain Metastases to SRS

Terminated

All 3 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
3